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monotherapy on chronic hepatitis B naı¨ve
patients
J. Dong1, L. Ma2, S.-Y. Wang3, Y.-Y. Zhu1, J.-J. Jiang1 *,
M.-N. Song4. 1Center of Liver Disease, the First Afﬁliated
Hospital of Fujian Medical University, Fuzhou, 2The third
hospital of Xiamen City, 3The branch Unit of Fuzhou Army
General Hospital, Fuzhou, 4The 174 Army Hospital, Xiamen
City, China
Objective: An open-label clinical trail was designed to
observe the efﬁcacy of domestic Adefovir dipivoxil (AGD,
Fujian Cosunter Pharmaceutical Co, LTD) monotherapy for
naı¨ve patients with chronic hepatitis B (CHB).
Methods: Patients with CHB or HBV-related compensated
cirrhosis were enrolled from 4 medical centers in Fujian
province. Each patient was treated with AGD 10mg daily.
Alanine aminotransferase (ALT), HBVDNA and HBeAg levels
were followed up to evaluate AGD efﬁcacy.
Results: A total of 114patients with complete medical
records were enrolled in this study. In this group, average
age was 37±12 years, 88 (77.2%) were male patients.
The mean ALT value is 252±261U/L, the mean HBVDNA
value is 6.4±1.6 log10 copies/ml, and 66 patients were
HBeAg positive. After taking AGD for 48 weeks, the HBVDNA
negative rate at 24 and 48 week was 54.6% (59/108) and
69.0% (60/87), respectively. In the sub-group of HBeAg-
positive patients, HBeAg seroconversion rate at 24 and 48
week was 25.8% (17/66) and 36.4% (24/66), respectively.
One patient with HBeAg-positive CHB achieved HBsAg
seroconversion at 48 weeks.
Conclusions: In patients with CHB or compensated cirrhosis
taking domestic AVD (AGD) 48 weeks, the HBVDNA negative
rate could reach 25.8%, and HBeAg seroconversion rate was
36.4%. Although these data was an open-label trial without
control, the primary result is encouraging at the higher
HBeAg seroconversion rate after AGD monotherapy. Further
follow-up is still being done.
PP-126 Dynamic changes and clinical signiﬁcance of
HBcAg speciﬁc cytotoxic T lymphocytes in
patients with acute hepatitis B
J. Li1 *, Y.P. Han1. 1Department of Infectious Diseases, the
First Afﬁliated Hospital with Nanjing Medical University,
China
Objective: To observe changes of HBcAg18 27 epitope
speciﬁc-CTL, ALT, HBV-DNAand HBsAg from peripheral blood,
and to explore roles of HBcAg-speciﬁc-CTL changes on
clearance of virus and liver injury in patients with AHB.
Methods: Thirty-three patients with AHB. Frequencies of the
speciﬁc CTL using HLA-A0201 limited HBcAg18 27 epitope
MHC-Pentamer and frequencies of T/B/NK/NKT cells were
dynamically detected by FCM. The serum ALT, HBV-DNA and
HBV serological markers were detected by methods of speed
analysis, PCR and Abbott chemiluminescent technology
respectively.
Results: Frequencies of HBcAg-speciﬁc-CTL were higher
during acute phase than those during recovery phase.
The apex time of HBcAg-speciﬁc-CTL frequencies lagged
behind HBV-DNA, HBsAg and ALT. The disappearance of
HBeAg in patients with high frequencies of HBV-speciﬁc-CTL
was earlier than that in patients with low frequencies of
HBcAg-speciﬁc-CTL. The peak frequencies of CD3+CD8+ cells
overlapped with the peak of frequencies of HBcAg-speciﬁc-
CTL in the second week after admission, and there was
signiﬁcant correlation between them. During early stage of
AHB, frequencies of NK and NKT cells were obviously lower
than those of normal control group and chronic hepatitis B,
and they became normal as recovery. For AHB, there was
a negative correlation between frequencies of NK cells and
dynamic changes of HBcAg-speciﬁc-CTL.
Conclusion: The disappearance of HBeAg was earlier
in patients with high frequencies of HBcAg-speciﬁc-
CTL. Monitiring frequencies of HBcAg-speciﬁc-CTL from
peripheral blood could be predicting clinical outcome
after HBV infection. Frequencies of CD8+ T cells indirectly
reﬂected changes of frequencies of HBcAg-speciﬁc-CTL
during acute HBV infection.
PP-127 Short-term therapy of entecavir versus
laminvudine for hepatitis B virus associated
acute hepatic failure
S. Lin1, J. Dong1, Y.-Y. Zhu1, Y.-R. Liu1, J. Chen1,
J.-J. Jiang1 *. 1Center of Liver Disease, the First Afﬁliated
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China
Aims: Lamivudine has been proved to be safe and effective
in treatment of hepatitis B virus associated acute hepatic
failure, but efﬁcacy of entecavir remains unclear. This
investigation aims to compare short-term therapy of
entecavir with laminvudine for hepatitis B virus associated
acute hepatic failure.
Methods: Forty-one patients were collected consecutively
infected with hepatitis B virus associated acute hepatic
failure. Fifteen were treated with entecavir 0.5mg daily,
and the other 26 were treated with laminvudine 100mg
daily. Acute liver failure is deﬁned as the evidence of
coagulation abnormality, usually an INR 1.5, and any degree
of mental alteration (encephalopathy) in a patient without
preexisting cirrhosis and with an illness of <26 weeks
duration. The primary outcome was the rate of death.
Results: There were no differences in clinical (age, gender,
MELD score and pretreatment liver function) and virological
characteristics (HBVDNA level and positive for HBeAg or
HBeAb) at the time of admission between lamivudine
group and entecavir group. None of them underwent liver
transplantation. During the median follow-up of 30 weeks,
the overall death rate was 34.14%. 6 of 26 patients
(23.08%) died during follow-up in lamivudine group, and
8 of 15 patients (53.33%) died in entecavir group (Figure 1).
Laminvudine group had greater reduction of prothrombin
time in the 3rd and 7th days than entecavir group comparing
to baseline. There were signiﬁcant difference between the
MELD scores at 14th, 21st and 28th day after administering
laminvudine or entecavir.
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Figure 1. Difference of mortality.
Conclusions: Short-term therapy of entecavir for hepatitis B
virus associated acute hepatic failure is not superior to
lamivudine.
